[Lactic acid depletion in the lungs of anesthetized dogs after prolonged adrenalin infusion].

W. Lochner,J. Piiper,E. Schurmeyer

DOI: https://doi.org/10.1007/BF00595646

Abstract:

What problem does this paper attempt to address?

A case report demonstrating the utility of next generation sequencing in analyzing serial samples from the lung following an infection with influenza A (H7N9) virus.

Yongfeng Hu,Yan Zhang,Xianwen Ren,Yingmei Liu,Yan Xiao,Li Li,Fan Yang,Haoxiang Su,Feng Liu,Haiying Liu,Bin Cao,Qi Jin

DOI: https://doi.org/10.1016/j.jcv.2015.12.013

2016-01-01

Abstract:BACKGROUND:Bacterial pneumonia is a well-recognized sequela of patient suffering from influenza, and a key factor, with cytokine dysregulation, that contribute to severe disease and mortality. OBJECTIVES:To obtain a comprehensive assessment of lung microbial community dynamics in a fatal influenza H7N9 case during the whole clinical course, we undertook a longitudinal study. STUDY DESIGN:Serial bronchoalveolar lavage fluid samples were collected from a H7N9 patient after illness onset, and the microbiome was characterized by using next-generation sequencing and microbiological approaches. Furthermore, the kinetics of circulating cytokine storms related to viral and secondary bacterial infection were analyzed. RESULTS:Within complex and dynamic communities, the lung microbiome with H7N9 infection were dominated by gram-negative bacteria, Acinetobacter baumannii after the viral invasion and during the whole clinical course. Sputum and blood culture confirmed the secondary bacterial infection with multidrug-resistant A. baumannii 9 days later. The dynamics of the bacterial infection with carbapenem-resistant A. baumannii correlated with antibiotic therapy. Our observations also indicated that sustained high levels of host inflammatory factors, consisting of a set of distinct cytokines associated with disease stage, may contribute to disease progression and death. CONCLUSIONS:This study demonstrates an initial attempt to explore the dynamic microbiome involved inH7N9 infection and its response to antimicrobial therapy, as well as host cytokine response to infection by using next-generation sequencing. These type of investigations with longitudinal follow-up to understand dynamics of microbial community and cytokines involved in lung infection may provide opportunities for development and optimization of targeted antimicrobial therapy and even new therapeutic strategies.
[Pneumocystis Jirovecii Pneumonia in Patients with Lung Cancer: A Review].

Ting Li,Jianying Zhou,Qing Wang

DOI: https://doi.org/10.3779/j.issn.1009-3419.2022.101.14

2022-01-01

Abstract:In recent years, with the widespread use of immunodepressant agents, Pneumocystis jirovecii pneumonia (PJP) has been significantly found in non-human immunodeficiency virus (HIV) patients, such as those with malignancies, post-transplantation and autoimmune diseases. Although the risk factors and management of PJP have been extensively studied in the hematologic tumor and post-transplant populations, the research on real tumor cases is insufficient. Lung cancer has been the most common tumor with the highest number of incidence and death worldwide, and the prognosis of lung cancer patients infected with PJP is poor in clinical practice. By reviewing the previous studies, this paper summarized the epidemiology and clinical manifestations of PJP in lung cancer patients, the risk factors and possible mechanisms of PJP infection in lung cancer patients, diagnosis and prevention, and other research progresses to provide reference for clinical application. .
Rare Co-Infection of the Lungs with EBV and Pneumocystis Carinii in a Patient with Kidney Cancer: a Case Report

Jing X Liu,Qin Zhang,Jing S Bai,Ai S Fu,Rong X Liu,Jing M Wang,Xin Y Zhou,Shan Gao,Qian C Chen,Jia B Zhang,Yan L Ge

DOI: https://doi.org/10.7754/Clin.Lab.2022.220511

2023-02-01

Abstract:Background: Epstein-Barr virus (EBV) is the primary agent of infectious mononucleosis, lymphoma, and naso-pharyngeal carcinoma, but rarely involves the lungs. Pneumocystis carinii is commonly found in patients with HIV infection and is not pathogenic when the host is healthy, but opportunistic infections can occur when the body is immunocompromised, causing pneumocystis pneumonia (PCP). It is rare for both diseases to occur in the lungs of the same patient. Methods: Next-generation sequencing (NGS), laboratory examination, chest CT scan, electronic bronchoscopy, and pathogenetic examination were used in this study. Results: Laboratory tests showed (1-3)-β-D-glucan of 889.47 pg/mL, negative human immunodeficiency virus (HIV) antibody, and negative Aspergillus immunological test. Chest CT showed multiple high-density shadows in both lungs, and EBV infection combined with Pneumocystis carinii pneumonia was confirmed by bronchoscopic biopsy and NGS examination. Conclusions: Elevated serum (1-3)-β-D-glucan is not a specific index for infectious diseases. Bronchoscopy and the NGS has high specificity in pathogen detection of infectious diseases.
A Fatal Co-infections of Aspergillus latus and Pneumocystis jirovecii in COVID-19 Pneumonia Patient: Case Report

Xiaoyong Li,Bin Wang,Dan Li,Lingling Lu,Guoping Li,Hui Shen,Lijuan Zhang,Xuefei Shi,Feng Hua,Jiayou Luo

DOI: https://doi.org/10.5812/jjm-149806

2024-11-07

Jundishapur Journal of Microbiology

Abstract:Introduction: For coronavirus disease 2019 (COVID-19) positive patients, co-infection with fungi has previously been reported. Owing to non-specific clinical manifestations and radiographic evidence, it is difficult to distinguish fungal infection from COVID-19 alone, resulting in delayed diagnosis and lack of appropriate treatment. Aspergillus latus infection, a newly rare species with life-threatening characteristics, requires rapid detection with accurate diagnosis to reduce mortality. However, there is little literature that provides a reference for a better understanding of this rare pathogen and guides medical practitioners in choosing the right diagnostics and therapies. Case Presentation: We reported a 67-year-old female complaining of fever, cough, and chest tightness, who had previously been hospitalized for a week due to initial COVID-19 pneumonia. On admission, clinical manifestations and radiological evidence were consistent with COVID-19 pneumonia, and there was no obvious improvement after anti-infective therapy. In terms of etiology for the patient, Galactomannan test was positive for Aspergillus genus, and Metagenomic next-generation sequencing further determined co-infections of A. latus and Pneumocystis jirovecii. Subsequently, isolation of A. latus was obtained through microbial culture. Despite targeted antifungal therapy, no clinical improvement was observed, possibly due to delayed diagnosis and treatment. Finally, the patient died of respiratory failure. Conclusions: This case report demonstrated that metagenomic next-generation sequencing is a fast, unbiased, culture-free approach that can increase the detection of rare pathogens, helping clinicians improve the accuracy of clinical diagnosis and take therapeutic action as quickly as possible. Clinicians should be aware of the risk of COVID-19-associated pulmonary Aspergillosis in COVID-19 patients, and we hope to optimize diagnosis and improve outcomes of COVID-19-associated pulmonary Aspergillosis.

microbiology
Pneumocystis jirovecii and Mycobacterium tuberculosis Pulmonary Coinfection in an HIV-Seronegative Patient: A Case Report and Literature Review

Shanchen Wei,Lianjun Lin

DOI: https://doi.org/10.2147/IDR.S370023

2022-07-30

Infection and Drug Resistance

Abstract:Shanchen Wei, Lianjun Lin Geriatric Department, Peking University First Hospital, Beijing, 100034, People's Republic of China Correspondence: Lianjun Lin, Geriatric Department, Peking University First Hospital, Xicheng District, Beijing, 100034, People's Republic of China, Email Background: Coinfection with Pneumocystis jirovecii and Mycobacterium tuberculosis is rare in HIV-seronegative patients. Because it is associated with unknown morbidity and a high mortality rate especially in patients with immunosuppression, health care practitioners should have a high index of suspicion when dealing with such patients. Case Presentation: A 66-year-old man with glucocorticoid therapy for 9 years had a fever after getting a cold and developed respiratory failure rapidly within 3 days. He was given trimethoprim-sulfamethoxazole empirically before Pneumocystis pneumonia (PCP) was confirmed with the presence of cysts in the sputum. Although there was a partial improvement of symptoms, an area of consolidation on the left upper lung lobe gradually enlarged. Bronchoscopy was performed 3 times and Mycobacterium tuberculosis infection was finally diagnosed. For 1 years, he was treated with standard antituberculosis agents, and his psychological well-being was managed using traditional Chinese medicine techniques. After 3 years of follow-up, his outcome was very good. Conclusion: HIV-seronegative patients on long-term glucocorticoid therapy in areas with a high incidence of Mycobacterium tuberculosis may be co-infected with Pneumocystis jirovecii . When opportunistic infections are suspected, diagnostic procedures including invasive ones should be performed as soon as possible and appropriate interventions need to be carried out promptly. Keywords: Mycobacterium tuberculosis , Pneumocystis jirovecii , PCP, HIV-seronegative, Immunosuppressed, corticosteroids Pneumocystis jirovecii and Mycobacterium tuberculosis are common opportunistic pulmonary pathogens in patients infected with human immunodeficiency virus (HIV). However, co-infection is extremely rare in HIV-seronegative patients; 1 while once occurred, it is severe and has a higher mortality rate. 2 Early diagnosis is difficult and delays in antibiotic treatment are more common in HIV-negative patients, which may lead to a poor prognosis. 3,4 Currently, there are no accurate diagnostic tools, so being aware of the possibility of coinfection and rapidly performing diagnostic procedures that may include invasive ones are key to improving clinical outcomes. A 66-year-old man presented and was admitted to the hospital with fever for 3 days and dyspnea for 1 day. The patient had been diagnosed with malignant pemphigus vulgaris and put on prednisolone, methylprednisolone and other immunosuppressive drugs for the past 9 years. On admission, he experienced respiratory failure. The absolute count of regulatory T lymphocytes was 156.67 cells/uL. The lactate dehydrogenase increased to 457 IU/L. The chest computed tomography (CT) scan revealed multiple flaky, fuzzy, and high-density opacities in both lungs (Figure 1A). The patient had been on steroids for a long time. He had obvious hypoxia and had never had any other respiratory symptoms or other infections. On respiratory examination, the patient did not have many rales in the lungs. The lung CT scan showed interstitial changes. PCP, usually treated with sulfonamides, was considered a possible etiology because of his immunocompromised state. Caspofungin is a good treatment of choice for Aspergillus infection, which could not be excluded. For other atypical pathogens, moxifloxacin should be added. Thus he was given trimethoprim-sulfamethoxazole (3 tablets, twice daily for 3 weeks), caspofungin (loading dose, 70mg infused over 1 hour; maintenance dose, 50 mg daily infused over 1 hour for 2 weeks), steroids, and moxifloxacin. Consequently, his respiratory function improved, and his body temperature dropped. PCP was confirmed 4 days later when cysts were found in the sputum ( Supplementary Material ). Figure 1 A chest CT scan of the 66-year-old man showing Pneumocystis jirovecii Pneumonia and Mycobacterium tuberculosis Infection. ( A ) A transverse chest CT scan obtained on the first day after admission showed multiple ground-glass opacities in both lungs (white arrow), and an area of consolidation in the left upper lung lobe (black arrow). ( B ) A follow-up chest CT scan obtained 1 month after admission showed the ground-glass opacities in both lungs were reduced (white arrow), but the left upper lobe consolidation was enlarged (black arrow). ( C ) A follow-up -Abstract Truncated-

pharmacology & pharmacy,infectious diseases
Clinical Features of Fatal Pandemic Influenza A/H1N1 Infection Complicated by Invasive Pulmonary Fungal Infection

Zhuxi Yu,Qin Gu,Beiyuan Zhang,Xiancheng Chen,Jian Tang,Yayi Hou,Wenkui Yu

DOI: https://doi.org/10.1007/s11046-019-00421-z

2020-01-01

Mycopathologia

Abstract:Background Severe pneumonia caused by influenza virus infection can be secondary to invasive pulmonary fungal (IPF) infection. Objectives This study aimed to summarize the incidence of IPF infection secondary to influenza virus infection and further explore its etiologic mechanism and high-risk factors. Methods All adult patients with confirmed influenza A (H1N1) virus infection admitted to the intensive care units (ICUs) of Nanjing Drum Hospital from November 2017 to March 2018 were retrospectively selected. The differences in baseline factors, risk factors, immune function and outcome parameters were studied between patients with and without IPF. Results Of the 19 critically ill patients with H1N1 infection, 11 (57.9%) developed IPF infection after 7 days of ICU admission. Two patients had proven and nine probable IPF infection. A difference in human leukocyte antigen-DR isotype (oHLA-DR; day 7-day 1) was found between the two groups. oHLA-DR (day 7-day 1) was higher in patients with no IPF infection than in those with IPF infection [(14.52 +/- 14.21)% vs ( - 11.74 +/- 20.22)%, P = 0.019]. The decline in HLA-DR indicated impaired immune function secondary to fungal infection in patients with H1N1 infection. Conclusions IPF infection was diagnosed in 57.9% of critically ill patients with H1N1 virus infection after a median of 7 days following ICU admission. A continuous decline in immune function could lead to the development of IPF infections. Dynamic monitoring of immune function may help in the early detection of IPF infection.
State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation.

H. Wen,Janet R. Cummings,J. Hockenberry,Laura M. Gaydos,B. Druss

DOI: https://doi.org/10.1001/jamapsychiatry.2013.2169

2013-12-01

JAMA Psychiatry

Abstract:IMPORTANCE The passage of the 2008 Mental Health Parity and Addiction Equity Act and the 2010 Affordable Care Act incorporated parity for substance use disorder (SUD) treatment into federal legislation. However, prior research provides us with scant evidence as to whether federal parity legislation will hold the potential for improving access to SUD treatment. OBJECTIVE To examine the effect of state-level SUD parity laws on state-aggregate SUD treatment rates and to shed light on the impact of the recent federal SUD parity legislation. DESIGN, SETTING, AND PARTICIPANTS We conducted a quasi-experimental study using a 2-way (state and year) fixed-effect method. We included all known specialty SUD treatment facilities in the United States and examined treatment rates from October 1, 2000, through March 31, 2008. Our main source of data was the National Survey of Substance Abuse Treatment Services, which provides facility-level information on specialty SUD treatment. INTERVENTIONS State-level SUD parity laws during the study period. MAIN OUTCOMES AND MEASURES State-aggregate SUD treatment rates in (1) all specialty SUD treatment facilities and (2) specialty SUD treatment facilities accepting private insurance. RESULTS The implementation of any SUD parity law increased the treatment rate by 9% (P < .001) in all specialty SUD treatment facilities and by 15% (P = .02) in facilities accepting private insurance. Full parity and parity only if SUD coverage is offered increased the SUD treatment rate by 13% (P = .02) and 8% (P = .04), respectively, in all facilities and by 21% (P = .03) and 10% (P = .04), respectively, in facilities accepting private insurance. CONCLUSIONS AND RELEVANCE We found a positive effect of the implementation of state SUD parity legislation on access to specialty SUD treatment. Furthermore, the positive association is more pronounced in states with more comprehensive parity laws. Our findings suggest that federal parity legislation holds the potential to improve access to SUD treatment.
Recent Advances in the Diagnosis of Pneumocystis Pneumonia.

Yinggai Song,Yi Ren,Xiaowen Wang,Ruoyu Li

DOI: https://doi.org/10.3314/mmj.16-00019

2016-01-01

Medical Mycology Journal

Abstract:Pneumocystis jirovecii is a prototypical opportunistic pathogen, causing an asymptomatic or mild infection in normal hosts and fulminating pneumonia (Pneumocystis pneumonia, PCP) in immunocompromised hosts. PCP is a leading cause of morbidity and mortality in immunocompromised patients such as AIDS patients. Microscopic detection of cysts and trophic forms of P. jirovecii in respiratory secretions is simple and useful but may underestimate the P. jirovecii infection. Conventional polymerase chain reaction (PCR) and nested PCR increase the sensitivity and specificity to identify PCP and provide an approach to discriminate PCP from pulmonary P. jirovecii colonization, but the targeted genes and cut-off value from quantitative real-time PCR remain to be determined. Serum (1-3)-β-D-glucan level and the specific serum antibody titer are ancillary indicators for PCP diagnosis. The successful cultivation of P. jirovecii in vitro is an important progress for PCP research. The diagnosis of PCP relies on the combination of these laboratory examinations as well as the clinical presentations.
COVID-19 and Pneumocystis jirovecii Pulmonary Coinfection-The First Case Confirmed through Autopsy

Ionuț Isaia Jeican,Patricia Inișca,Dan Gheban,Flaviu Tăbăran,Maria Aluaș,Veronica Trombitas,Victor Cristea,Carmen Crivii,Lia Monica Junie,Silviu Albu

DOI: https://doi.org/10.3390/medicina57040302

2021-03-24

Abstract:Background: Establishing the diagnosis of COVID-19 and Pneumocystisjirovecii pulmonary coinfection is difficult due to clinical and radiological similarities that exist between the two disorders. For the moment, fungal coinfections are underestimated in COVID-19 patients. Case presentation: We report the case of a 52-year-old male patient, who presented to the emergency department for severe dyspnea and died 17 h later. The RT-PCR test performed at his admission was negative for SARS-CoV-2. Retesting of lung fragments collected during autopsy revealed a positive result for SARS-CoV-2. Histopathological examination showed preexisting lesions, due to comorbidities, as well as recent lesions: massive lung thromboses, alveolar exudate rich in foam cells, suprapleural and intra-alveolar Pneumocystisjirovecii cystic forms, and bilateral adrenal hemorrhage. Conclusion: COVID-19 and P.jirovecii coinfection should be considered, particularly in critically ill patients, and we recommend the systematic search for P. jirovecii in respiratory samples.
Coinfection of Cytomegalovirus, Pneumocystis jirovecii pneumonia, COVID-19, and Mycobacterium colombiense in an AIDS patient: A case report

Zhongbao Zuo,Rongrong Zheng,Feng Li,Aifang Xu,Jinchuan Shi

DOI: https://doi.org/10.1016/j.heliyon.2024.e31729

IF: 3.776

2024-05-22

Heliyon

Abstract:We present an AIDS patient coinfected with Cytomegalovirus, Pneumocystis jirovecii pneumonia, nontuberculous mycobacteria, and COVID-19, who finally recovered from the coinfection. The 36-year-old man had two hospitalizations. In the first hospitalization, the patient was diagnosed with Cytomegalovirus, Pneumocystis jirovecii pneumonia, HIV, and COVID-19 quickly and accurately, and the corresponding treatment worked well. The second hospitalization can be divided into four stages: (1) Persistent fever period; (2) Persistent fever and Pulmonary Progression; (3) ICU period; and (4) Pneumothorax period. During the second hospitalization, the diagnosis of Mycobacterium colombiense was hard because the NGS, acid-fast bacilli, and culture of vomit, sputum, and bronchoalveolar lavage fluid were all negative. Still, we detected acid-fast bacilli in the blood mycobacterium culture. In conclusion, we report a severe pneumonia AIDS patient coinfected with Cytomegalovirus, Pneumocystis jirovecii pneumonia, COVID-19, and Mycobacterium colombiense who finally recovered from the disease. Nontuberculous mycobacteria infection is common in HIV patients, but bronchoalveolar lavage fluid NGS cannot identify nontuberculous mycobacteria in our report. Traditional blood culture was useful in detecting acid-fast bacilli in our study and then detecting the pathogens with NGS. Combining traditional microbial culture and emerging rapid NGS methods is more conducive to clinical diagnosis and treatment.
Pneumocystis jirovecii diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature

Qing-Wei Cheng,Hong-Li Shen,Zhi-Hui Dong,Qian-Qian Zhang,Ya-Fen Wang,Jin Yan,Yu-Sheng Wang,Ning-Gang Zhang

DOI: https://doi.org/10.12998/wjcc.v11.i4.866

2023-02-06

World Journal of Clinical Cases

Abstract:BACKGROUND: The advent of molecular targeted agents and immune checkpoint inhibitors has greatly improved the treatment of advanced renal cell carcinoma (RCC), thus significantly improving patient survival. The incidence of rare drug-related adverse events has gained increased attention.CASE SUMMARY: We report a patient with advanced RCC treated with multiple lines of molecular targeted agents and immune checkpoint inhibitors, who developed a pulmonary infection after treatment with everolimus in combination with lenvatinib. Determining the pathogenic organism was difficult, but it was eventually identified as <i>Pneumocystis jirovecii</i> by next-generation sequencing (NGS) of bronchoscopic alveolar lavage fluid (BALF) and successfully treated with trimethoprim-sulfamethoxazole.CONCLUSION: Rare pulmonary infections caused by molecular targeted agents are not uncommon in clinical practice, but their diagnosis is difficult. Evaluating BALF with NGS is a good method for rapid diagnosis of such infections.

medicine, general & internal
Pneumocystis jirovecii and Legionella pneumophila coinfection in a patient with diffuse large B-cell lymphoma: A case report

Wen-Hao Wu,Tian-Chen Hui,Qing-Qing Wu,Cheng-An Xu,Zhe-Wen Zhou,Shou-Hao Wang,Wei Zheng,Qiao-Qiao Yin,Xi Li,Hong-Ying Pan

DOI: https://doi.org/10.12998/wjcc.v9.i28.8595

2021-10-06

World Journal of Clinical Cases

Abstract:BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin's lymphoma. R-CHOP is a protocol for long-term chemotherapy for DLBCL patients. Long-term chemotherapy can lead to low immunity and increase the risk of opportunistic pathogen infections in immunocompromised patients.CASE SUMMARY: We report a case of coinfection with Pneumocystis jirovecii (P. jirovecii) and Legionella pneumophila (L. pneumophila) in a patient with DLBCL. The patient was a 40-year-old female who was diagnosed with DLBCL and was admitted due to pulmonary infection. P. jirovecii and L. pneumophila were detected in her bronchoalveolar lavage fluid by hexamine silver staining, isothermal amplification and metagenomic sequencing.CONCLUSION: To the best of our knowledge, this is the first case of P. jirovecii and L. pneumophila coinfection found in a DLBCL patient. Clinicians should be aware of the risk of complicated infection in patients undergoing long-term chemotherapy.

medicine, general & internal
[Epidemiological Characteristics of Pneumocystis Jirovecii Infection and Colonization in Non-Aids Patients].

S Long,X D Mu,C Zhang,L Su,P Jia,P N Zhou,G F Wang

DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2018.30.009

2018-01-01

Abstract:Objective: To analyze the epidemiological characteristics of Pneumocystis jirovecii infection and colonization in non-AIDS patients. Methods: From January 2010 to December 2017, bronchoalveolar lavage fluid (BALF) was detected by Grocott's methenamine silver (GMS) staining and real-time fluorescence quantitative PCR (qPCR) in non-AIDS patients with bronchoscopic alveolar lavage at Peking University First Hospital. At the same time, Pneumocystis jirovecii was detected in the environment of the hospital. Results: Within 8 years, Pneumocystis jirovecii were detected in BALF of a total of 1 407 non-AIDS patients. GMS staining was performed in all these 1 407 cases, of which 114 (8.10%) cases were with Pneumocystis jirovecii infection and 3 (0.21%) cases with colonization. There were totally 946 non-AIDS immunocompromised patients, of which 113 (11.95%) cases were infected and 2 (0.21%) cases with colonization; there were 461 non-AIDS immunocompetent patients, of which only 1 (0.22%) case was infected and 1 (0.22%) case with colonization. GMS staining and qPCR were both performed in 196 cases, of which 36 (18.37%) cases were infected and 33 (16.84%) cases with colonization. There were totally 175 non-AIDS immunocompromised patients, of which 36 (20.57%) cases were infected and 30 (17.14%) cases with colonization; there were 21 non-AIDS immunocompetent patients, of which no one was infected and 3 (14.29%) cases with colonization. By means of GMS staining and qPCR, no Pneumocystis jiroveci were detected in the environment of Peking University First Hospital. Conclusions:Pneumocystis pneumonia is rare in immunocompetent patients, but not in non-AIDS immunocompromised patients. And colonization is rare in both of them. There may be no Pneumocystis jiroveci in the environment.
The short spermatodesm of Arge pagana (Hymenoptera: symphyta).

J. Lino-Neto,H. Dolder,K. Mancini,D. Mercati,R. Dallai

DOI: https://doi.org/10.1016/j.tice.2007.11.004

2008-06-01

Abstract:
Linkage between an X-chromosome marker (deutan color blindness) and bipolar affective illness. Occurrence in the family of a lithium carbonate-responsive schizo-affective proband.

M. Baron

DOI: https://doi.org/10.1001/ARCHPSYC.1977.01770180107010

1977-06-01

Archives of General Psychiatry

Abstract:Studies with X-chromosome markers in mental illness have been limited to the diagnostic concept of primary affective disorders. The present study is the first to our knowledge to demonstrate statistically measurable linkage between color blindness and manic-depressive illness in a family identified by a schizo-affective proband. Linkage data and lithium carbonate response in the proband suggest that the schizophreniform-affective spectrum in members of the pedigree may reflect a genetically distinct disorder. The use of a genetic marker as a heuristic diagnostic criterion in a subgroup of heredofamilial psychoses with unclear diagnostic boundaries is proposed.
[Report of 2 Cases of Novel Influenza A (H1N1) Virus Infection Complicated with Pneumonia and Hypoxemia].

Jing-Hong Dai,Hou-Rong Cai,Yong-Feng Yang,Chang-Qing Teng

DOI: https://doi.org/10.3760/cma.j.issn.1001-0939.2010.02.002

2010-01-01

Abstract:OBJECTIVE:to improve understanding of the novel influenza A (H1N1) virus infection complicated with pneumonia.METHOD:clinical presentations, radiological data, laboratory data and treatments of 2 patients with pneumonia caused by the novel influenza A (H1N1) virus were retrospectively analyzed.RESULTS:one patient was a middle-aged woman, and the other was a young man with a history of asthma. Both patients had fever (temperatures more than 39 degrees C), cough, and dyspnea. At the time of admission, both patients had hypoxemia. Chest computed tomography (CT) scan showed patchy distribution of consolidation and ground-glass opacity mainly in peripheral subpleural regions, as well as peribrochovascular lesions with air-bronchogram. The decreased and lymphocytes, elevated lactate dehydrogenase and creatine kinase were found in both patients. After admission, the patients received oseltamivir with a dose of 75 mg twice a day for a minimum of 5 days. Other treatments included antibiotics and methylprednisolone. One patient needed intermittent non-invasive ventilation for respiratory distress. Both patients recovered and the opacities on their chest CT were almost absorbed. WBC counts increased to normal and the levels of LDH and CK decreased.CONCLUSIONS:patients with the novel influenza A (H1N1) virus infection may develop pneumonia. The manifestations are non-specific. Chest CT scan reveals patchy distribution of consolidation and ground-glass opacity. In addition to antiviral therapy, glucocorticoids may have some effects on the pulmonary lesions and be useful for improving the clinical conditions.
Severe influenza A virus pneumonia complicated with Curvularia lunata infection: Case Report

Yanqing Zhang,Haixia Li,Ling Chen,Fei Feng,Liping Liu,Qinghong Guo

DOI: https://doi.org/10.3389/fcimb.2023.1289235

IF: 6.073

2023-12-15

Frontiers in Cellular and Infection Microbiology

Abstract:Human infection with Curvularia lunata ( C. lunata ) is exceptionally rare. A 23-year-old female patient contracted both bacterial and Curvularia lunata infections during influenza A virus infection. Multiple etiological tests were performed repeatedly during hospitalization due to fluctuations in condition. On the 17th day after hospital admission, mold hyphae were discovered in the pathogen culture of the patient's bronchoalveolar lavage fluid during one of these examinations. The patient was suspected to have a filamentous fungal infection. Consequently, we further obtained sputum samples for fungal culture, which confirmed the diagnosis of Curvularia infection. The patient, in this case, was in a critical condition, experiencing complications of lung abscess, pneumothorax, sepsis, and multiorgan failure. Despite prompt initiation of antifungal therapy including amphotericin B cholesteryl sulfate complex and isavuconazole upon detection of the fungal infection and concurrent administration of active organ function support treatment, the patient's condition rapidly deteriorated due to compromised immune function. Ultimately, on the 27th day of treatment, the patient succumbed to septic shock and multiple organ dysfunction syndrome. This is the first case of Curvularia lunata infection in our hospital. In this paper, we aim to raise awareness of Curvularia lunata infection and to emphasize that the possibility of this fungal infection should be considered in patients with severe pneumonia caused by influenza A virus and that empirical antifungal therapy should be given promptly when the patient has invasive lung damage.

immunology,microbiology
Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China

Xiaojing Wu,Ying Cai,Xu Huang,Xin Yu,Li Zhao,Fan Wang,Quanguo Li,Sichao Gu,Teng Xu,Yongjun Li,Binghuai Lu,Qingyuan Zhan

DOI: https://doi.org/10.3201/eid2606.200299

IF: 16.126

2020-06-01

Emerging Infectious Diseases

Abstract:We report co-infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A virus in a patient with pneumonia in China. The case highlights possible co-detection of known respiratory viruses. We noted low sensitivity of upper respiratory specimens for SARS-CoV-2, which could further complicate recognition of the full extent of disease.

immunology,infectious diseases
Combined hemophagocytic syndrome and thrombotic microangiopathy due to mixed infection with influenza virus and pneumococcal pneumonia

Takashi Ishiguro,Ayako Kojima,Taisuke Shimizu,Norikatsu Mita,Seiichiro Kuroiwa,Noboru Takayanagi

DOI: https://doi.org/10.1002/ccr3.1842

2018-11-22

Abstract:Development of hemophagocytic syndrome and thrombotic microangiopathy due to community-acquired pneumonia is rare, but delayed management of these complications can lead to a poor prognosis. Infection by both Streptococcus pneumoniae and influenza virus can cause these complications; thus, physicians should pay attention to them when treating influenza-associated pneumococcal pneumonia.
Occupational contact dermatitis from golden shrimp plant (Pachystachys lutea)

E. Paulsen,Stine Lasthein Andersen,K. Andersen

DOI: https://doi.org/10.1111/j.1600-0536.2009.01531.x

2009-05-01

Contact Dermatitis

Abstract:

[Lactic acid depletion in the lungs of anesthetized dogs after prolonged adrenalin infusion].

A case report demonstrating the utility of next generation sequencing in analyzing serial samples from the lung following an infection with influenza A (H7N9) virus.

[Pneumocystis Jirovecii Pneumonia in Patients with Lung Cancer: A Review].

Rare Co-Infection of the Lungs with EBV and Pneumocystis Carinii in a Patient with Kidney Cancer: a Case Report

A Fatal Co-infections of Aspergillus latus and Pneumocystis jirovecii in COVID-19 Pneumonia Patient: Case Report

Pneumocystis jirovecii and Mycobacterium tuberculosis Pulmonary Coinfection in an HIV-Seronegative Patient: A Case Report and Literature Review

Clinical Features of Fatal Pandemic Influenza A/H1N1 Infection Complicated by Invasive Pulmonary Fungal Infection

State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation.

Recent Advances in the Diagnosis of Pneumocystis Pneumonia.

COVID-19 and Pneumocystis jirovecii Pulmonary Coinfection-The First Case Confirmed through Autopsy

Coinfection of Cytomegalovirus, Pneumocystis jirovecii pneumonia, COVID-19, and Mycobacterium colombiense in an AIDS patient: A case report

Pneumocystis jirovecii diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature

Pneumocystis jirovecii and Legionella pneumophila coinfection in a patient with diffuse large B-cell lymphoma: A case report

[Epidemiological Characteristics of Pneumocystis Jirovecii Infection and Colonization in Non-Aids Patients].

The short spermatodesm of Arge pagana (Hymenoptera: symphyta).

Linkage between an X-chromosome marker (deutan color blindness) and bipolar affective illness. Occurrence in the family of a lithium carbonate-responsive schizo-affective proband.

[Report of 2 Cases of Novel Influenza A (H1N1) Virus Infection Complicated with Pneumonia and Hypoxemia].

Severe influenza A virus pneumonia complicated with Curvularia lunata infection: Case Report

Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China

Combined hemophagocytic syndrome and thrombotic microangiopathy due to mixed infection with influenza virus and pneumococcal pneumonia

Occupational contact dermatitis from golden shrimp plant (Pachystachys lutea)